Onyx Healthcare (ROCO:6569) Revenue: NT$1,381 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6569 Onyx Healthcare Inc ROCO:6569
76 GF Score
Price NT$92.50
GF Value NT$128.99
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Onyx Healthcare Revenue?

Onyx Healthcare ROCO:6569 -1.28% 76 Revenue is NT$1,381 Mil as of Mar. 2026. GuruFocus rates ROCO:6569 with a GF Score™ of 76/100 and a GF Value™ of NT$128.99 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Onyx Healthcare's revenue for the three months ended in Mar. 2026 was NT$377 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was NT$1,381 Mil. Onyx Healthcare's Revenue per Share for the three months ended in Mar. 2026 was NT$9.64. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$35.26.

Warning Sign:

Onyx Healthcare Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Onyx Healthcare was 7.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -7.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -2.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 0.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Onyx Healthcare's highest 3-Year average Revenue per Share Growth Rate was 15.00% per year. The lowest was -7.60% per year. And the median was 0.85% per year.


Onyx Healthcare  (ROCO:6569) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Onyx Healthcare Revenue Related Terms


Onyx Healthcare Revenue Historical Data

* Premium members only.

The historical data trend for Onyx Healthcare's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onyx Healthcare Revenue Chart

Onyx Healthcare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,201.76 1,600.27 1,492.86 1,241.25 1,313.29

Onyx Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 309.94 357.47 330.14 315.74 377.37

ROCO:6569 vs VEEV, BTSG, HQY: Revenue Comparison

For the Health Information Services subindustry, Onyx Healthcare's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Onyx Healthcare Revenue vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Onyx Healthcare's Revenue distribution charts can be found below:

* The bar in red indicates where Onyx Healthcare's Revenue falls into.


ROCO:6569
76GF Score
Onyx Healthcare Inc ROCO:6569
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onyx Healthcare Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,381 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of NT$1,381 Mil mean?
Onyx Healthcare (ROCO:6569) has a Revenue of NT$1,381 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Onyx Healthcare and its competitors.
Is Onyx Healthcare's Revenue too high?
Onyx Healthcare's current Revenue is NT$1,381 Mil. Overall, Onyx Healthcare has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Onyx Healthcare's Revenue compare to VEEV and BTSG?
Onyx Healthcare's Revenue of NT$1,381 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Onyx Healthcare and its competitors. Onyx Healthcare's current Revenue is NT$1,381 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Onyx Healthcare (ROCO:6569) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$128.99, compared to a current price of NT$92.50 — trading 28.3% below its estimated fair value. The current Revenue is NT$1,381 Mil. Onyx Healthcare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Onyx Healthcare (ROCO:6569), the current Revenue is NT$1,381 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Onyx Healthcare (ROCO:6569) Overvalued in 2026?

Based on GuruFocus' analysis, Onyx Healthcare stock appears to be undervalued. The current stock price of NT$92.50 is trading 28.3% below its estimated GF Value™ of NT$128.99. GuruFocus considers Onyx Healthcare to be Modestly Undervalued.

Key valuation signals for ROCO:6569:

  • Revenue: NT$1,381 Mil
  • GF Value™: NT$128.99 vs. price of NT$92.50 (28.3% below fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Onyx Healthcare Business Description

Address No. 135, Lane 235, Baoqiao Road, 4th Floor, Xindian District, New Taipei, TWN, 231028
Onyx Healthcare Inc is engaged in designing, manufacturing, and trading of medical computers and peripherals. The company provides medical products such as AI Ready Medical PC and Tablet, Medical PC & Monitor for Digital OR (ACCEL), Telemedicine, Medical Cart Computer(Venus), Medical Power Panel PC (Mini Venus), Power Bank (UPower), Battery Management System (ORION), Mobile Medical Tablet (MD), Professional Medical All in One PC (ZEUS), etc. It operates in Taiwan, the United States, Europe, and Other countries and generates maximum revenue from Taiwan.
76GF Score

Get the complete analysis for ROCO:6569

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$92.50
Price
NT$128.99
GF Value